These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27338508)

  • 21. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
    Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B
    Diabetes Obes Metab; 2018 May; 20(5):1111-1120. PubMed ID: 29266675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
    Otsuka Y; Yamaguchi S; Furukawa A; Kosuda M; Nakazaki M; Ishihara H
    Endocr J; 2015; 62(2):133-43. PubMed ID: 25328079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.
    Kobayashi K; Yokoh H; Sato Y; Takemoto M; Uchida D; Kanatsuka A; Kuribayashi N; Terano T; Hashimoto N; Sakurai K; Hanaoka H; Ishikawa K; Onishi S; Yokote K;
    Diabetes Obes Metab; 2014 Aug; 16(8):761-5. PubMed ID: 24447683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
    Schwarz B; Gouveia M; Chen J; Nocea G; Jameson K; Cook J; Krishnarajah G; Alemao E; Yin D; Sintonen H
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():43-55. PubMed ID: 18435673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Zerilli T; Pyon EY
    Clin Ther; 2007 Dec; 29(12):2614-34. PubMed ID: 18201579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Nieuwdorp M; Groen AK; Cahen DL; van Raalte DH
    Diabetes Obes Metab; 2016 Dec; 18(12):1217-1225. PubMed ID: 27451030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).
    Lumb AN; Gallen IW
    Diabet Med; 2009 Feb; 26(2):189-90. PubMed ID: 19236626
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study.
    Henry RR; Staels B; Fonseca VA; Chou MZ; Teng R; Golm GT; Langdon RB; Kaufman KD; Steinberg H; Goldstein BJ
    Diabetes Obes Metab; 2014 Mar; 16(3):223-30. PubMed ID: 23909985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.
    Katsuno T; Ikeda H; Ida K; Miyagawa J; Namba M
    Endocr J; 2013; 60(6):733-42. PubMed ID: 23386390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up.
    Nakamura T; Iwanaga Y; Miyaji Y; Nohara R; Ishimura T; Miyazaki S;
    Cardiovasc Diabetol; 2016 Mar; 15():54. PubMed ID: 27036865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study.
    Sakura H; Hashimoto N; Sasamoto K; Ohashi H; Hasumi S; Ujihara N; Kasahara T; Tomonaga O; Nunome H; Honda M; Iwamoto Y;
    BMC Endocr Disord; 2016 Dec; 16(1):70. PubMed ID: 27905912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
    Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    J Atheroscler Thromb; 2022 Jan; 29(1):24-37. PubMed ID: 33342939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia.
    Fukuda M; Doi K; Sugawara M; Mochizuki K
    J Diabetes Investig; 2019 Mar; 10(2):383-391. PubMed ID: 30136435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea.
    Khaloo P; Asadi Komeleh S; Alemi H; Mansournia MA; Mohammadi A; Yadegar A; Afarideh M; Esteghamati S; Nakhjavani M; Esteghamati A
    J Endocrinol Invest; 2019 Jul; 42(7):851-857. PubMed ID: 30535871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis.
    Gray LJ; Dales J; Brady EM; Khunti K; Hanif W; Davies MJ
    Diabetes Obes Metab; 2015 Jul; 17(7):639-48. PubMed ID: 25777247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
    Oe H; Nakamura K; Kihara H; Shimada K; Fukuda S; Takagi T; Miyoshi T; Hirata K; Yoshikawa J; Ito H;
    Cardiovasc Diabetol; 2015 Jun; 14():83. PubMed ID: 26084668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
    Takayanagi R; Uchida T; Kimura K; Yamada Y
    Biol Pharm Bull; 2018; 41(2):153-157. PubMed ID: 29386477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.